SwePub
Sök i SwePub databas

  Extended search

Träfflista för sökning "WFRF:(Elbert A) "

Search: WFRF:(Elbert A)

  • Result 1-17 of 17
Sort/group result
   
EnumerationReferenceCoverFind
1.
  • Ruilope, LM, et al. (author)
  • Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial
  • 2019
  • In: American journal of nephrology. - : S. Karger AG. - 1421-9670 .- 0250-8095. ; 50:5, s. 345-356
  • Journal article (peer-reviewed)abstract
    • <b><i>Background:</i></b> Among people with diabetes, those with kidney disease have exceptionally high rates of cardiovascular (CV) morbidity and mortality and progression of their underlying kidney disease. Finerenone is a novel, nonsteroidal, selective mineralocorticoid receptor antagonist that has shown to reduce albuminuria in type 2 diabetes (T2D) patients with chronic kidney disease (CKD) while revealing only a low risk of hyperkalemia. However, the effect of finerenone on CV and renal outcomes has not yet been investigated in long-term trials. <b><i>Patients and</i></b> <b><i>Methods:</i></b> The Finerenone in Reducing CV Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD) trial aims to assess the efficacy and safety of finerenone compared to placebo at reducing clinically important CV and renal outcomes in T2D patients with CKD. FIGARO-DKD is a randomized, double-blind, placebo-controlled, parallel-group, event-driven trial running in 47 countries with an expected duration of approximately 6 years. FIGARO-DKD randomized 7,437 patients with an estimated glomerular filtration rate ≥25 mL/min/1.73 m<sup>2</sup> and albuminuria (urinary albumin-to-creatinine ratio ≥30 to ≤5,000 mg/g). The study has at least 90% power to detect a 20% reduction in the risk of the primary outcome (overall two-sided significance level α = 0.05), the composite of time to first occurrence of CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure. <b><i>Conclusions:</i></b> FIGARO-DKD will determine whether an optimally treated cohort of T2D patients with CKD at high risk of CV and renal events will experience cardiorenal benefits with the addition of finerenone to their treatment regimen. Trial Registration: EudraCT number: 2015-000950-39; ClinicalTrials.gov identifier: NCT02545049.
  •  
2.
  •  
3.
  •  
4.
  •  
5.
  • Carr, S.B., et al. (author)
  • Factors associated with clinical progression to severe COVID-19 in people with cystic fibrosis: A global observational study
  • 2022
  • In: Journal of Cystic Fibrosis. - : Elsevier BV. - 1569-1993. ; 21:4, s. E221-E231
  • Journal article (peer-reviewed)abstract
    • Background: This international study aimed to characterise the impact of acute SARS-CoV-2 infection in people with cystic fibrosis and investigate factors associated with severe outcomes. Methods Data from 22 countries prior to 13th December 2020 and the introduction of vaccines were included. It was de-identified and included patient demographics, clinical characteristics, treatments, outcomes and sequalae following SARS-CoV-2 infection. Multivariable logistic regression was used to investigate factors associated with clinical progression to severe COVID-19, using the primary outcome of hospitalisation with supplemental oxygen. Results: SARS-CoV-2 was reported in 1555 people with CF, 1452 were included in the analysis. One third were aged <18 years, and 9.4% were solid-organ transplant recipients. 74.5% were symptomatic and 22% were admitted to hospital. In the non-transplanted cohort, 39.5% of patients with ppFEV1<40% were hospitalised with oxygen verses 3.2% with ppFEV >70%: a 17-fold increase in odds. Worse outcomes were independently associated with older age, non-white race, underweight body mass index, and CF-related diabetes. Prescription of highly effective CFTR modulator therapies was associated with a significantly reduced odds of being hospitalised with oxygen (AOR 0.43 95%CI 0.31-0.60 p<0.001). Transplanted patients were hospitalised with supplemental oxygen therapy (21.9%) more often than non-transplanted (8.8%) and was independently associated with the primary outcome (Adjusted OR 2.45 95%CI 1.27-4.71 p=0.007). Conclusions: This is the first study to show that there is a protective effect from the use of CFTR modulator therapy and that people with CF from an ethnic minority are at more risk of severe infection with SARS-CoV-2. © 2022
  •  
6.
  •  
7.
  •  
8.
  • Sciarretta, A., et al. (author)
  • A control benchmark on the energy management of a plug-in hybrid electric vehicle
  • 2014
  • In: Control Engineering Practice. - : Pergamon Press. - 0967-0661 .- 1873-6939. ; 29, s. 287-298
  • Journal article (peer-reviewed)abstract
    • A benchmark control problem was developed for a special session of the IFAC Workshop on Engine and Powertrain Control, Simulation and Modeling (E-COSM 12), held in Rueil-Malmaison, France, in October 2012. The online energy management of a plug-in hybrid-electric vehicle was to be developed by the benchmark participants. The simulator, provided by the benchmark organizers, implements a model of the GM Voltec powertrain. Each solution was evaluated according to several metrics, comprising of energy and fuel economy on two driving profiles unknown to the participants, acceleration and braking performance, computational performance. The nine solutions received are analyzed in terms of the control technique adopted (heuristic rule-based energy management vs. equivalent consumption minimization strategies, ECMS), battery discharge strategy (charge depleting-charge sustaining vs. blended mode), ECMS implementation (vector-based vs. map-based), ways to improve the implementation and improve the computational performance. The solution having achieved the best combined score is compared with a global optimal solution calculated offline using the Pontryagins minimum principle-derived optimization tool HOT.
  •  
9.
  •  
10.
  •  
11.
  • Evensen, L, et al. (author)
  • Thin detectors for the CHICSi Delta E-E telescope
  • 1997
  • In: IEEE TRANSACTIONS ON NUCLEAR SCIENCE. - : IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC. - 0018-9499. ; 44:3, s. 629-634
  • Journal article (peer-reviewed)abstract
    • A pilot series of 10 mu m to 15 mu m thin silicon detectors has been made for the Delta E-E telescopes in the CHICSi detector system. This system will operate gt the CELSIUS heavy ion storage ring in Uppsala, Sweden, Delta E-E telescopes provide isotope i
  •  
12.
  •  
13.
  •  
14.
  • Paterson, R. W., et al. (author)
  • SILK studies — capturing the turnover of proteins linked to neurodegenerative diseases
  • 2019
  • In: Nature Reviews Neurology. - : Springer Science and Business Media LLC. - 1759-4758 .- 1759-4766. ; 15:7, s. 419-427
  • Journal article (peer-reviewed)abstract
    • Alzheimer disease (AD) is one of several neurodegenerative diseases characterized by dysregulation, misfolding and accumulation of specific proteins in the CNS. The stable isotope labelling kinetics (SILK) technique is based on generating amino acids labelled with naturally occurring stable (that is, nonradioactive) isotopes of carbon and/or nitrogen. These labelled amino acids can then be incorporated into proteins, enabling rates of protein production and clearance to be determined in vivo and in vitro without the use of radioactive or chemical labels. Over the past decade, SILK studies have been used to determine the turnover of key pathogenic proteins amyloid-β (Aβ), tau and superoxide dismutase 1 (SOD1) in the cerebrospinal fluid of healthy individuals, patients with AD and those with other neurodegenerative diseases. These studies led to the identification of several factors that alter the production and/or clearance of these proteins, including age, sleep and disease-causing genetic mutations. SILK studies have also been used to measure Aβ turnover in blood and within brain tissue. SILK studies offer the potential to elucidate the mechanisms underlying various neurodegenerative disease mechanisms, including neuroinflammation and synaptic dysfunction, and to demonstrate target engagement of novel disease-modifying therapies. © 2019, Springer Nature Limited.
  •  
15.
  •  
16.
  •  
17.
  •  
Skapa referenser, mejla, bekava och länka
  • Result 1-17 of 17

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view